Sequenom (SQNM)
Sequenom Revenues: 14.92M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
SQNM Revenues Rankings
| Overall | 18th percentile | 3632 of 4432 |
| Sector | 39th percentile | 284 of 471 in Healthcare |
| Industry | 60th percentile | 52 of 132 in Biotechnology |
SQNM Revenues Range, Past 5 Years
| Minimum | 8.688M | Mar 2009 |
| Maximum | 15.48M | Dec 2011 |
| Average | 11.72M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these SQNM related companies
SQNM News
Over-hyped: Verinata: 1,100 tests in initial weeks. $SQNM did > 10,000 commercial MaterniT21 PLUS test samples in 2012, as of May 12.
about 42 minutes ago by abubnic
about 42 minutes ago by abubnic
Lol @biotech verinata numbers better than sequenoms first three months $sqnm #doyourresearchtool
about 6 hours ago by Prudentrader77
about 6 hours ago by Prudentrader77
$SQNM competitor verinata with very weak test volume just PRd http://stks.co/42uL watch $SQNM for a shortsqueeze today
about 7 hours ago by biotech
about 7 hours ago by biotech
$SQNM clearly manipulated, daily moves +/-5% on no news & light volume. Stock is too cheap here, I am betting with SAC for a POP & squeeze!
about 2 days ago by pro_con
about 2 days ago by pro_con
@ChasinCheddar Trigger happy traders sold on the $SQNM news today. You are right. Stock is way too cheap. Long position.
about 2 days ago by abubnic
about 2 days ago by abubnic
$SQNM is too good of a stock to be in the low 4's......no position but I may start one soon.
about 2 days ago by ChasinCheddar
about 2 days ago by ChasinCheddar
Sequenom Announces Participation at the Jefferies Global Healthcare Conference
May 29, 7:30AM PR Newswire
May 29, 7:30AM PR Newswire
mostly for the rush, ive decided to go all in with 40K purchase of either $SQNM or $CLSN...what's your vote? I won't hold u liable :)
about 6 days ago by Creyedr
about 6 days ago by Creyedr
$SQNM Stock under accumulation in b4 JUN 15 patent hearing; SAC Capitol initiating a 5.4% stake strongly indicates a SQNM victory coming.
about 8 days ago by pro_con
about 8 days ago by pro_con
$sqnm getting beat up recently, maybe the money is slowing moving towards $GNOM
about 8 days ago by ChasinCheddar
about 8 days ago by ChasinCheddar
$SQNM was down 10.9% on Friday following news that they didn't get the Coventry Health acct. But they'll get others. Long-term growth stock
about 10 days ago by abubnic
about 10 days ago by abubnic
$SQNM Rebound from options exp selloff, news of 10k tests not widely disseminated. Upside pressure this wk
about 11 days ago by pro_con
about 11 days ago by pro_con
$SQNM 5,100 MaterniT21 tests processed between March 31 and May 14, wow
about 13 days ago by biotech
about 13 days ago by biotech
Auriga Securities on Sequenom (SQNM): Coventry (CVH) Giveth, Coventry Taketh Away
May 18, 10:49AM Street Insider
May 18, 10:49AM Street Insider
$SQNM going back up - todays option expiration might even make this green !?
about 13 days ago by biotech
about 13 days ago by biotech
Sequenom (SQNM) Says Coventry Health Terminated Network Participation Agreement
May 17, 4:34PM Street Insider
May 17, 4:34PM Street Insider
Sequenom's Management Presents at Bank of America Merrill Lynch 2012 Healthcare Conference (Transcript)
May 15, 9:30PM Seeking Alpha
May 15, 9:30PM Seeking Alpha
Blood-based Prenatal Test Maker Ariosa Diagnostics Gets Boost From Partnership With LabCorp
May 10, 10:43AM Forbes
May 10, 10:43AM Forbes
Sequenom (SQNM) to Provide Coverage for Sequenom CMM MaterniT21 PLUS LDT
May 09, 7:31AM Street Insider
May 09, 7:31AM Street Insider
Sequenom Announces Participation at the Bank of America Merrill Lynch Health Care Conference
May 07, 7:30AM PR Newswire
May 07, 7:30AM PR Newswire
Trovagene Announces Validation Program for Trans-Renal K-RAS Mutation Detection in Pancreatic Cancer
Apr 30, 12:50PM PR Newswire
Apr 30, 12:50PM PR Newswire
Wedbush Upgrades Sequenom (SQNM) to Neutral; Limited Near-Term Negative Catalysts
Apr 24, 8:38AM Street Insider
Apr 24, 8:38AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| SQNM | 3.835 | -0.24 | -6.00% | 467.32M |
| SQM | 52.14 | -1.37 | -2.56% | 14.08B |
| SQI | 15.95 | +0.43 | +2.77% | 343.77M |
| SPYG | 61.81 | -0.24 | -0.39% | |
| SPY | 132.03 | +0.27 | +0.20% | |
| SPXU | 53.80 | -0.32 | -0.59% | |
| SPWR | 4.985 | -0.14 | -2.64% | 600.88M |
| SPW | 71.99 | -1.85 | -2.51% | 3.798B |
| SPU | 1.53 | +0.06 | +4.08% | 37.76M |
| SPTN | 16.77 | +0.12 | +0.72% | 380.79M |